BBS-Bioactive Bone Substitutes Oyj (BONEH.HE)

EUR 0.06

(-4.3%)

Operating Expenses Summary of BBS-Bioactive Bone Substitutes Oyj

BBS-Bioactive Bone Substitutes Oyj's latest annual operating expenses in 2023 was 3.36 Million EUR , up 15.11% from previous year.
BBS-Bioactive Bone Substitutes Oyj's latest quarterly operating expenses in 2024 Q2 was 375.00 EUR , down -52.53% from previous quarter.
BBS-Bioactive Bone Substitutes Oyj reported a annual operating expenses of 2.92 Million EUR in annual operating expenses 2022, up 16.21% from previous year.
BBS-Bioactive Bone Substitutes Oyj reported a annual operating expenses of 2.51 Million EUR in annual operating expenses 2021, down -1.87% from previous year.
BBS-Bioactive Bone Substitutes Oyj reported a quarterly operating expenses of 375.00 EUR for 2024 Q2, down -52.53% from previous quarter.
BBS-Bioactive Bone Substitutes Oyj reported a quarterly operating expenses of 3.14 Million EUR for 2023 FY, up 7.8% from previous quarter.

Annual Operating Expenses Chart of BBS-Bioactive Bone Substitutes Oyj (2023 - 2014)

Historical Annual Operating Expenses of BBS-Bioactive Bone Substitutes Oyj (2023 - 2014)

Year	Operating Expenses	Operating Expenses Growth
2023	3.36 Million EUR	15.11%
2022	2.92 Million EUR	16.21%
2021	2.51 Million EUR	-1.87%
2020	2.56 Million EUR	79.13%
2019	1.43 Million EUR	336.12%
2018	-605.73 Thousand EUR	-146.74%
2017	1.29 Million EUR	154.12%
2016	510 Thousand EUR	-5.38%
2015	539 Thousand EUR	120.59%
2014	244.34 Thousand EUR	0.0%

Year	Operating Expenses	Operating Expenses Growth
2024 Q1	790.00 EUR	-99.95%
2024 Q2	375.00 EUR	-52.53%
2023 FY	3.14 Million EUR	7.8%
2023 Q2	1.46 Million EUR	186177.0%
2023 Q4	1.68 Million EUR	188051.17%
2023 Q1	787.00 EUR	-99.94%
2023 Q3	895.03 EUR	-99.94%
2022 Q2	1.36 Million EUR	185247.24%
2022 Q4	1.35 Million EUR	187848.32%
2022 Q3	723.00 EUR	-99.95%
2022 FY	2.92 Million EUR	16.21%
2022 Q1	737.81 EUR	-99.94%
2021 Q3	652.29 EUR	-99.94%
2021 Q2	1.15 Million EUR	190710.71%
2021 Q4	1.18 Million EUR	181686.25%
2021 Q1	604.77 EUR	-99.95%
2021 FY	2.51 Million EUR	-1.87%
2020 Q1	687.89 EUR	-99.89%
2020 Q3	593.12 EUR	-99.95%
2020 Q4	1.15 Million EUR	194659.88%
2020 FY	2.56 Million EUR	79.13%
2020 Q2	1.27 Million EUR	185385.07%
2019 Q3	328.83 EUR	-99.95%
2019 FY	1.43 Million EUR	336.12%
2019 Q4	613.91 Thousand EUR	186597.52%
2019 Q1	386.30 EUR	34.43%
2019 Q2	696.6 Thousand EUR	180228.71%
2018 Q3	287.36 EUR	-51.31%
2018 FY	-605.73 Thousand EUR	-146.74%
2018 Q4	287.36 EUR	0.0%
2018 Q1	590.23 EUR	-68.23%
2018 Q2	590.23 EUR	-0.0%
2017 FY	1.29 Million EUR	154.12%
2017 Q1	273.23 EUR	0.0%
2017 Q2	273.23 EUR	0.0%
2017 Q3	1858.06 EUR	580.04%
2017 Q4	1858.06 EUR	0.0%
2016 FY	510 Thousand EUR	-5.38%
2015 FY	539 Thousand EUR	120.59%
2014 FY	244.34 Thousand EUR	0.0%

Peer Operating Expenses Comparison of BBS-Bioactive Bone Substitutes Oyj

Name	Operating Expenses	Operating Expenses Difference
Modulight Oyj	17.11 Million EUR	80.35%
Nexstim Plc	3.51 Million EUR	4.355%
Revenio Group Oyj	18.8 Million EUR	82.111%